![Jennifer Robinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jennifer Robinson
Investor Relations Contact chez VERVE THERAPEUTICS, INC.
Postes actifs de Jennifer Robinson
Sociétés | Poste | Début | Fin |
---|---|---|---|
VERVE THERAPEUTICS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - |
Historique de carrière de Jennifer Robinson
Anciens postes connus de Jennifer Robinson
Sociétés | Poste | Début | Fin |
---|---|---|---|
DYAX CORP. | Investor Relations Contact | 01/10/2011 | 01/04/2016 |
Public Communications Contact | 01/10/2011 | 01/04/2016 | |
RA PHARMACEUTICALS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - | |
DECIPHERA PHARMACEUTICALS, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - | |
ADICET BIO, INC. | Investor Relations Contact | 01/06/2018 | - |
Public Communications Contact | 01/06/2018 | - |
Formation de Jennifer Robinson
Dartmouth College | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Investor Relations Contact | 5 |
Public Communications Contact | 5 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
VERVE THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Dyax Corp.
![]() Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
resTORbio, Inc.
![]() resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Deciphera Pharmaceuticals, Inc.
![]() Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
![]() Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Jennifer Robinson
- Expérience